-
21.发明授权Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem 失效合成N，N-二甲基-3-（4-甲基）苯甲酰基丙酰胺是唑吡旦的关键中间体公开(公告)号：US06921839B2
公开(公告)日：2005-07-26
申请号：US10363377
申请日：2001-08-28
Applicant: Yatendra Kumar , Mohan Prasad , Azok Nath
Inventor： Yatendra Kumar , Mohan Prasad , Azok Nath
IPC: C07C231/02 , C07C235/78 , C07D471/04
CPC classification number: C07D471/04 , C07C231/02 , C07C235/78
Abstract: The present invention relates to an improved and industrially advantageous process for the preparation of N,N-dimethyl-3-(4-methyl)benzoyl propionamide of Formula I, which is a key intermediate in the synthesis of zolpidem hemitartrate, a non-benzodiazepine hypnotic agent. The process includes reacting 3-(4-methyl)-benzoyl propionic acid of Formula IV, with alkyl chloroformate or pivaloyl chloride to get a mixed anhydride of Formula V; and reacting the mixed anhydride of Formula V with dimethylamine of Formula VI to get the N,N-dimethyl-3-(4-methyl)benzoyl propionamide of Formula I.
Abstract translation: 本发明涉及用于制备式I的N，N-二甲基-3-（4-甲基）苯甲酰基丙酰胺的改进和工业上有利的方法，其是合成灭丹霉素酒渣酸盐，非苯并二氮杂的关键中间体 催眠药。 该方法包括使式IV的3-（4-甲基） - 苯甲酰基丙酸与氯甲酸烷基酯或新戊酰氯反应，得到式V的混合酸酐; 并使式V的混合酸与式VI的二甲胺反应得到式I的N，N-二甲基-3-（4-甲基）苯甲酰基丙酰胺。
-
公开(公告)号：US08916713B2
公开(公告)日：2014-12-23
申请号：US13812066
申请日：2011-07-15
Applicant: Pranab Chatterjee , Asok Nath , Sarbjot Singh Sokhi , Mohan Prasad
Inventor： Pranab Chatterjee , Asok Nath , Sarbjot Singh Sokhi , Mohan Prasad
IPC: C07D277/56
CPC classification number: C07D277/56
Abstract: An improved and efficient process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid (febuxostat) that is substantially free from amide by-product is provided.
Abstract translation: 提供了一种改进和有效的制备基本上不含酰胺副产物的2- [3-氰基-4-（2-甲基丙氧基）苯基] -4-甲基噻唑-5-羧酸（febustostat）的方法。
-
公开(公告)号：US08609854B2
公开(公告)日：2013-12-17
申请号：US13497835
申请日：2010-09-24
Applicant: Jagdev Singh Jaryal , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
Inventor： Jagdev Singh Jaryal , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC: C07D213/63 , C07D213/70 , A61K31/44
CPC classification number: C07D213/81
Abstract: The present invention provides a process for the preparation of sorafenib tosylate, comprising contacting sorafenib free base with p-toluenesulphonic acid in water.
Abstract translation: 本发明提供了一种制备甲苯磺酸索拉非尼的方法，包括将索拉非尼游离碱与对甲苯磺酸在水中接触。
-
公开(公告)号：US20130204002A1
公开(公告)日：2013-08-08
申请号：US13638399
申请日：2011-03-29
Applicant: Anu Mittal , Anmol Kumar Ray , Mahavir Singh Khanna , Rajesh Kumar Thaper , Mohan Prasad
Inventor： Anu Mittal , Anmol Kumar Ray , Mahavir Singh Khanna , Rajesh Kumar Thaper , Mohan Prasad
IPC: C07D401/12
CPC classification number: C07D401/12
Abstract: The present invention relates to a process for the preparation of crystalline dexlansoprazole.
Abstract translation: 本发明涉及一种制备结晶右兰索拉唑的方法。
-
公开(公告)号：US08445698B2
公开(公告)日：2013-05-21
申请号：US12666606
申请日：2008-06-28
Applicant: Dattatray B. Patil , Killol Patel , Ashok Prasad , Mohan Prasad
Inventor： Dattatray B. Patil , Killol Patel , Ashok Prasad , Mohan Prasad
IPC: C07D487/00
CPC classification number: C07D471/14 , C07D471/04 , C07D471/12
Abstract: The present invention relates to a process for the preparation of cis-intermediate of Formula II, which is useful synthetic intermediates in the preparation of tadalafil.
Abstract translation: 本发明涉及制备式II的顺式 - 中间体的方法，其在制备他达拉非方面是有用的合成中间体。
-
Patent Agency Ranking
26.发明授权Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof 失效厄洛替尼或其药学上可接受的盐的制备方法公开(公告)号：US08440823B2
公开(公告)日：2013-05-14
申请号：US13258961
申请日：2010-03-26
Applicant: Balaguru Murugesan , Anandam Vempali , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
Inventor： Balaguru Murugesan , Anandam Vempali , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC: C07D401/00
CPC classification number: C07D239/94
Abstract: The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate.
Abstract translation: 本发明涉及制备式I的厄洛替尼或其药学上可接受的盐的方法。 本发明还涉及制备三氟醋酸埃洛替尼的方法。 本发明还涉及一种名为E型的埃洛替尼三氟乙酸盐的结晶形式及其制备方法。 本发明还涉及从埃罗替尼三氟醋酸盐制备盐酸埃罗替尼的方法。
-
公开(公告)号：US08404854B2
公开(公告)日：2013-03-26
申请号：US12703004
申请日：2010-02-09
Applicant: Yatendra Kumar , Mahavir Singh Khanna , Mohan Prasad
Inventor： Yatendra Kumar , Mahavir Singh Khanna , Mohan Prasad
IPC: C07D401/12
CPC classification number: C07D401/12 , A61K31/4439
Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.
-
28.发明申请PROCESSES FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE FORM A AND ERLOTINIB HYDROCHLORIDE FORM B 审中-公开ERLOTINIB氢氯酸盐形式A和ERLOTINIB氢氯化物形式B的制备方法公开(公告)号：US20120302749A1
公开(公告)日：2012-11-29
申请号：US13509031
申请日：2010-11-12
Applicant: Balaguru Murugesan , Anandam Vempali , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
Inventor： Balaguru Murugesan , Anandam Vempali , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC: C07D239/94
CPC classification number: C07D239/94
Abstract: The present invention relates to processes for the preparation of erlotinib hydrochloride Form A and erlotinib hydrochloride Form B. (I).
Abstract translation: 本发明涉及制备盐酸埃罗替尼形式A和盐酸埃洛替尼B型（I）的方法。
-
29.发明申请公开(公告)号：US20120277426A1
公开(公告)日：2012-11-01
申请号：US13375548
申请日：2010-06-02
Applicant: Deepak Mohanlal Jain , Maneck Khurana , Hiten Sharadchandra Mehta , Abhay Tatiya , Asok Nath , Sanjay Mahadeo Gade , Mohan Prasad , Subhash Dhar
Inventor： Deepak Mohanlal Jain , Maneck Khurana , Hiten Sharadchandra Mehta , Abhay Tatiya , Asok Nath , Sanjay Mahadeo Gade , Mohan Prasad , Subhash Dhar
IPC: C07D413/06
CPC classification number: C07D413/06
Abstract: The present invention provides a process for preparation of crystalline aprepitant having not more than 15% by weight of Form I content which comprises, a) dissolving aprepitant in a suitable solvent to obtain a solution, b) cooling the solution to 10-15° C., c) optionally seeding the solution with aprepitant Form I crystals, d) adding an anti-solvent to the solution, and e) isolating crystalline aprepitant having not more than 15% by weight of Form I content.
Abstract translation: 本发明提供一种制备具有不超过15重量％的形式I含量的结晶阿拉曲百特的方法，其包括：a）将阿瑞消制剂溶解在合适的溶剂中以获得溶液，b）将溶液冷却至10-15℃ c）任选地用溶液形式I晶体接种该溶液，d）向该溶液中加入抗溶剂，和e）分离不超过15重量％的形式I含量的结晶阿拉米特。
-
30.发明申请PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM I OF L-MALIC ACID SALT OF SUNITINIB 审中-公开制备硫酸铵的结晶形式I的方法公开(公告)号：US20120271056A1
公开(公告)日：2012-10-25
申请号：US13508907
申请日：2010-11-12
Applicant: Sudhir Singh Sanwal , Saridi Madhava Dileep Kumar , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
Inventor： Sudhir Singh Sanwal , Saridi Madhava Dileep Kumar , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC: C07D209/46 , A61P1/00 , A61K31/4035
CPC classification number: C07D403/06
Abstract: The present invention relates to a process for the preparation of crystalline Form I of the L-malic acid salt of sunitinib.
Abstract translation: 本发明涉及一种制备舒尼替尼的L-苹果酸盐的晶型I的方法。
-
-
-
-
-
-
-
-
-
Search Results
96
records
(took 0.027 seconds)
